Back from the Brink: EGFR Inhibition in Gastroesophageal Cancer.

Openshaw M RDavid J PinatoNicola Valeri

Published in: Clinical cancer research : an official journal of the American Association for Cancer Research (2021)

Gastroesophageal adenocarcinomas (GEA) remain difficult to treat with limited targeted therapeutics. Negative results from randomized trials of EGFR inhibitors (EGFRi) in patients with molecularly unselected GEA have hampered the development of EGFRi in the gastroesophageal cancer space. A recent study reopens the game.See related article by Corso et al., p. 3126.

Keyphrases

papillary thyroid
small cell lung cancer
squamous cell
epidermal growth factor receptor
lymph node metastasis
small molecule
squamous cell carcinoma
childhood cancer
young adults
drug induced